Tumor chemosensitivity assays are helpful for personalized cytotoxic treatments in cancer patients

Basit Öğe Kaydı
dc.authoridDidem Karakaş Zeybek / 0000-0002-3781-6834en_US
dc.authoridEngin Ulukaya / 0000-0003-4875-5472en_US
dc.authorscopusidDidem Karakaş Zeybek / 56422040600
dc.authorscopusidEngin Ulukaya / 6602927353
dc.authorwosidDidem Karakaş Zeybek / L-6682-2018
dc.authorwosidEngin Ulukaya / K-5792-2018
dc.contributor.authorUlukaya, Engin
dc.contributor.authorKarakaş Zeybek, Didem
dc.contributor.authorDimas, Konstantinos
dc.date.accessioned2021-07-05T11:23:08Z
dc.date.available2021-07-05T11:23:08Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractTumor chemosensitivity assays (TCAs), also known as drug response assays or individualized tumor response tests, have been gaining attention over the past few decades. Although there have been strong positive correlations between the results of these assays and clinical outcomes, they are still not considered routine tests in the care of cancer patients. The correlations between the assays' results (drug sensitivity or resistance) and the clinical evaluations (e.g., response to treatment, progression-free survival) are highly promising. However, there is still a need to design randomized controlled prospective studies to secure the place of these assays in routine use. One of the best ideas to increase the value of these assays could be the combination of the assay results with the omics technologies (e.g., pharmacogenetics that gives an idea of the possible side effects of the drugs). In the near future, the importance of personalized chemotherapy is expected to dictate the use of these omics technologies. The omics relies on the macromolecules (Deoxyribonucleic acid -DNA-, ribonucleic acid -RNA-) and proteins (meaning the structure) while TCAs operate on living cell populations (meaning the function). Therefore, wise combinations of TCAs and omics could be a highly promising novel landscape in the modern care of cancer patients.en_US
dc.identifier.citationUlukaya, E., Karakas, D., & Dimas, K. (2021). Tumor Chemosensitivity Assays Are Helpful for Personalized Cytotoxic Treatments in Cancer Patients. Medicina, 57(6), 636.en_US
dc.identifier.doi10.3390/medicina57060636en_US
dc.identifier.issn1010-660Xen_US
dc.identifier.issn1648-9144en_US
dc.identifier.issue6en_US
dc.identifier.pmid34205407en_US
dc.identifier.scopus2-s2.0-85109170456en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.3390/medicina57060636
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1874
dc.identifier.volume57en_US
dc.identifier.wosWOS:000666186000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorUlukaya, Engin
dc.institutionauthorKarakaş Zeybek, Didem
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofMEDICINA-LITHUANIAen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectTumor Chemosensitivity Assayen_US
dc.subjectDrug Response Assayen_US
dc.subjectTreatmenten_US
dc.subjectPharmacogeneticsen_US
dc.titleTumor chemosensitivity assays are helpful for personalized cytotoxic treatments in cancer patientsen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
92.pdf
Boyut:
1.4 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Moleküler Biyoloji ve Genetik Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Makale Koleksiyonu